Treat-to-target insulin titration algorithms when initiating long or intermediate acting insulin in type 2 diabetes

Journal of Diabetes Science and Technology

Volumn 1, Issue 4, 2007, Pages 540-548

  Strange, Poul ^a  

^a Poul Strange Consulting LLC   (United States)

Author keywords

Algorithm; Basal; Detemir; Fasting glucose; FPG; Glargine; Insulin; NPH; Severe hypoglycemia; Titration

Indexed keywords

EID: 84859771070     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229680700100412     Document Type: Article

References (32)

1. FDA. Humulin N Pen Information for the patient. http://www fda gov/cder/foi/label/2004/18781s079lbl pdf 2004 September 3.
2. FDA. Lantus US Package Insert. http://www fda gov/cder/foi/label/2007/ 021081s024lbl pdf 2007 April 25.
3. FDA. Levemir US Package Insert. http://www fda gov/cder/foi/label/2005/ 021536lbl pdf 2005 May 16.
4. Riddle M, Hart J, Bingham P, Garrison C, McDaniel P. Combined therapy for obese type 2 diabetes: suppertime mixed insulin with daytime sulfonylurea. Am J Med Sci. 1992 March; 303(3):151-6.
5. Yki-Jarvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care. 2000 August; 23(8):1130-6.
6. Schwartz S, Sievers R, Strange P, Lyness WH, Hollander P. Insulin 70/30 mix plus metformin versus triple oral therapy in the treatment of type 2 diabetes after failure of two oral drugs: efficacy, safety, and cost analysis. Diabetes Care. 2003 August; 26(8):2238-43.
7. Riddle MC, Schneider J. Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Glimepiride Combination Group. Diabetes Care. 1998 July; 21(7):1052-7.
8. D'Orazio P, Burnett RW, Fogh-Andersen N, Jacobs E, Kuwa K, Kulpmann WR, Larsson L, Lewenstam A, Maas AH, Mager G, Naskalski JW, Okorodudu AO. Approved IFCC recommendation on reporting results for blood glucose (abbreviated). Clin Chem. 2005 September; 51(9):1573-6.
9. Holman RR, Turner RC. A practical guide to basal and prandial insulin therapy. Diabet Med. 1985 January; 2(1):45-53.
10. Gerstein HC, Yale JF, Harris SB, Issa M, Stewart JA, Dempsey E. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucoselowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study. Diabet Med. 2006 July; 23(7):736-42.
11. Davies M, Storms F, Shutler S, Bianchi-Biscay M, Gomis R. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care. 2005 June; 28(6):1282-8.
12. Yki-Jarvinen H, Kauppinen-Makelin R, Tiikkainen M, Vahatalo M, Virtamo H, Nikkila K, Tulokas T, Hulme S, Hardy K, McNulty S, Hanninen J, Levanen H, Lahdenpera S, Lehtonen R, Ryysy L. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia. 2006 March; 49(3):442-51.
13. Yki-Jarvinen H, Juurinen L, Alvarsson M, Bystedt T, Caldwell I, Davies M, Lahdenpera S, Nijpels G, Vahatalo M. INITIATE (INITiate Insulin by Aggressive Titration and Education). A randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups. Diabetes Care. 2007 March 23.
14. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003 November; 26(11):3080-6.
15. Hermansen K, Davies M, Derezinski T, Martinez RG, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care. 2006 June; 29(6):1269-74.
16. Tanenberg R, Zisman A, Stewart J. Diabetes. 2006;55 Suppl 1:A135.
17. Meneghini L, Schwartz S, SoltesRak E, Harris A, Strange P. Improved glycemic control with insulin glargine vs pioglitazone as add-on therapy in patients with type 2 diabetes uncontrolled on sulfonylurea or metformin monotherapy. Late breaking abstract 10 poster at the ADA annual meeting; 2005.
18. Hollander P, Sugimoto D, Kilo C, Harris A, Vlajnic A. Combination therapy with insulin glargine plus metformin but not glargine plus sulfonylurea provides similar glycemic control to triple oral combination in patients with type 2 diabetes failing dual oral agents. Late breaking abstract 9 poster at the ADA annual meeting; 2005.
19. Fritsche A, Schweitzer MA, Haring HU. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med. 2003 June 17;138(12):952-9.
20. Eliaschewitz FG, Calvo C, Valbuena H, Ruiz M, Aschner P, Villena J, Ramirez LA, Jimenez J. Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride. Arch Med Res. 2006 May; 37(4):495-501.
21. Kennedy L, Herman WH, Strange P, Harris A. Impact of active versus usual algorithmic titration of basal insulin and point-ofcare versus laboratory measurement of HbA1c on glycemic control in patients with type 2 diabetes: the Glycemic Optimization with Algorithms and Labs at Point of Care (GOAL A1C) trial. Diabetes Care. 2006 January; 29(1):1-8.
22. Kennedy L, Herman WH. Renal status among patients using metformin in a primary care setting. Diabetes Care. 2005 April; 28(4):922-4.
23. Strowig SM, Viles-Santa ML, Raskin P. Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetes. Diabetes Care. 2002 October; 25(10):1691-8.
24. Buse JB, Gumbiner B, Mathias NP, Nelson DM, Faja BW, Whitcomb RW. Troglitazone use in insulin-treated type 2 diabetic patients. The Troglitazone Insulin Study Group. Diabetes Care. 1998 September; 21(9):1455-61.
25. Strowig SM, Viles-Santa ML, Raskin P. Improved glycemic control without weight gain using triple therapy in type 2 diabetes. Diabetes Care. 2004 July; 27(7):1577-83.
26. Karter AJ, Moffet HH, Liu J, Parker MM, Ahmed AT, Ferrara A, Selby JV. Achieving good glycemic control: initiation of new antihyperglycemic therapies in patients with type 2 diabetes from the Kaiser Permanente Northern California Diabetes Registry. Am J Manag Care. 2005 April; 11(4):262-70.
27. Lantus Plus Orals Equals Glycemic Control. http://www lantus com/hcp/glycemic/adding aspx 2007; May 25.
28. Shanik M, Xu Y, Škrha J, Dankner R, Zick Y, Roth J. Insulin resistance and hyperinsulinemia: is hyperinsulinemia the cart or the horse? Diabetes Care. 2007. In press 2007.
29. Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Jarvinen H. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care. 2005 February; 28(2):254-9.
30. Raskin P, Allen E, Hollander P, Lewin A, Gabbay RA, Hu P, Bode B, Garber A. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care. 2005 February; 28(2):260-5.
31. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2005 October 18;143(8):559-69.
32. Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care. 2006 March; 29(3):554-9.